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Abstract Kinase domains are the type of protein domain
most commonly found in genes associated with tumorigen-
esis. Because of this, the human kinome (the protein kinase
component of the genome) represents a promising source of
cancer biomarkers and potential targets for novel anti-
cancer therapies. Alterations in the human colon kinome
during the progression from normal colon (NC) through
adenoma (AD) to adenocarcinoma (AC) were investigated
using integrated transcriptomic and proteomic datasets.
Two hundred thirty kinase genes and 42 kinase proteins
showed differential expression patterns (fold change≥1.5)
in at least one tissue pair-wise comparison (AD vs. NC, AC
vs. NC, and/or AC vs. AD). Kinases that exhibited similar
trends in expression at both the mRNA and protein levels
were further analyzed in individual samples of NC (n=20),
AD (n=39), and AC (n=24) by quantitative reverse
transcriptase PCR. Individual samples of NC and tumor
tissue were distinguishable based on the mRNA levels of a
set of 20 kinases. Altered expression of several of these
kinases, including chaperone activity of bc1 complex-like
(CABC1) kinase, bromodomain adjacent to zinc finger
domain protein 1B (BAZ1B) kinase, calcium/calmodulin-
dependent protein kinase type II subunit delta (CAMK2D),
serine/threonine-protein kinase 24 (STK24), vaccinia-
related kinase 3 (VRK3), and TAO kinase 3 (TAOK3),
has not been previously reported in tumor tissue. These
findings may have diagnostic potential and may lead to the
development of novel targeted therapeutic interventions for
colorectal cancer.
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Introduction
Protein phosphorylation is a central element of numerous
cell signaling pathways, including those that control cell
growth, differentiation, apoptosis, and invasion. The rele-
vance of phosphorylation is underscored by the fact that the
protein kinase (PK) complement of the genome (the so-
called kinome) comprises about 2% of all human genes,
encoding 518 distinct tyrosine or serine/threonine PKs
which are involved in the phosphorylation of over one third
of all intracellular proteins [1].
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malignant transformation and tumor development [2]. A
global survey of somatic mutations in a diverse set of
human cancer genomes showed that the PK domain is the
most commonly represented domain in so-called cancer
genes, with the strongest evidence of overrepresentation
compared to what would be expected by chance [3].
Mutations in PKs may be involved in the development of
a significant proportion of cancers, including colorectal
cancer (CRC) [4].
Preliminary evaluation of transcriptomic datasets from a
microarray study of oncogenic signaling in CRC [5]
revealed that probe sets which represented PK genes have
the potential to distinguished normal colon (NC) epithelium
from adenomas (ADs) and adenocarcinomas (ACs) (not
shown). Therefore, in the present study, combined tran-
scriptomic and proteomic datasets from our integrated
microarray- and mass spectrometry (MS)-based study [6]
were mined for PKs whose expression concordantly
changed at both the transcriptional and the protein levels
during the progression from NC through AD to AC. To our
knowledge, a comprehensive approach such as the one
taken here for analyzing the tumor kinome has not been
reported previously.
Materials and methods
PK probe sets and peptides
The identifiers (IDs) of the probe sets (Affymetrix) and
proteins (Swiss-Prot) were used to select the respective PKs
from our previously derived transcriptomic and proteomic
datasets established on pooled colonic tissue samples [6].
The putative PKs were searched using the term “protein
kinase” to browse the Gene Ontology (GO) database, and
the selection was further verified based on data available in
the following databases: UniProt (http://www.uniprot.org/),
GeneCards (http://www.genecards.org/), Human Protein
Reference Database (http://www.hprd.org/), Bioinformatic
Harvester (http://www.harvester.fzk.de), PhosphoSitePlus
(http://www.posphosite.org/), Pfam (http://www.pfam.
sanger.ac.uk/), Brenda (http://www.brenda-enzyme.org/),
and the kinome database of Manning et al. [1].
Functional annotation and biological pathway analysis
The gene and protein lists were assessed for known
biological interactions and involvement in canonical path-
ways using Ingenuity Pathway Analysis (IPA; Ingenuity
Systems, Mountain View, CA, http://www.ingenuity.com).
The gene/protein IDs were imported into IPA for core
analysis evaluation. The Fisher’s exact test with the
Benjamini–Hochberg correction for multiple hypotheses
was used to determine the probability that the association
between the dataset and the biological function or the
canonical pathway was due to random chance alone. A p
value of less than 0.01 was considered statistically
significant. The ratio of the number of genes/proteins in
the dataset that mapped to the pathway and the total number
of molecules that made up the pathway provided an
estimate of the extent of pathway involvement.
Quantitative reverse transcriptase PCR
RNA concentrations were determined in 83 colonic tissue
samples using quantitative reverse transcriptase PCR (qRT-
PCR),asdescribed previously[6]. The clinical characteristics
of the patients and the histopathological characteristics
of the analyzed tissue samples are presented in
Table S1. The sequences of all primers are listed in
Table S2. Differences were evaluated using the Mann–
Whitney U test in GraphPad Prism 5 (GraphPad Software,
Inc., CA, USA). A p value of less than 0.05 was
considered statistically significant.
Results
Identification of PKs using combined transcriptomic
and proteomic datasets
To select sets of PK genes and proteins, combined
transcriptomic and proteomic datasets previously acquired
for pooled NC, AD, and AC tissues in our integrated
microarray- and MS-based study [6] were reevaluated.
From the 24,740 probe sets that remained after filtering
according to the GCRMA+LVS algorithm, 792 probe sets
were identified corresponding to 410 PK genes (Table S3).
Of these, 308 (75%) and 69 (17%) encoded serine/
threonine kinases (STKs) and tyrosine kinases (TKs),
respectively. Among 3,886 distinct proteins (identified by
at least two peptides), 90 were confirmed as PKs; 63 (70%)
and 24 (27%) were STKs and TKs, respectively. In total,
411 PK transcripts and/or PK proteins were identified (see
Table S4 for the full list), with 89 PKs common to both
datasets.
Comparative analysis of PK gene expression and protein
levels
The first component of principal component analysis (PCA)
revealed that PK mRNA levels distinguished NC and
neoplastic tissues (Fig. 1a), whereas protein levels distin-
guished AD from NC and AC (Fig. 1b). These results
suggested that the changes in PK mRNA and protein
448 J Mol Med (2012) 90:447–456expression during CRC progression are to some extent
quantitatively different.
Pair-wise comparisons revealed that 164, 81, and 199
genes were differentially expressed (≥1.5-fold) in AD vs.
NC, AC vs. AD, and AC vs. NC, respectively (Fig. S1a), as
calculated by geometric mean ratio values for probe sets
representing a single PK gene. However, a substantially
smaller number of PKs were differentially expressed at the
protein level, with 23, 22, and 26 proteins exhibiting
different expression levels in AD vs. NC, AC vs. AD, and
AC vs. NC, respectively (Fig. S1b). In total, the levels of
230 transcripts and 42 proteins were different in at least one
pair-wise comparison (Table S5), which most likely reflects
the differences in the sensitivity of microarray and MS
techniques.
Comparison of expression trends and functional annotation
of differentially expressed PKs
Based on pair-wise comparisons and using a threshold
of fold change (FC)≥1.5, PK levels were assigned to
one of five expression trends, as shown in Table 1.
Trend 3 was the most prevalent among the differentiating
PK transcripts and proteins; however, strikingly, trend 5
was almost four times more frequent among proteins than
genes.
Functional annotation of the differentially expressed PK
genes and proteins and assignment to Ingenuity canonical
signaling pathways was carried out using IPA software
(Tables S6 and S7). Of note, 26 of the 36 process categories
that were significantly associated with the PK proteins
were also among the top 40 categories for the PK
genes. Furthermore, the top five canonical pathways
identified for the protein dataset were among the top 23
pathways identified for the gene dataset. Thus, while
there were differences observed in the expression trends
for PK mRNAs and proteins during CRC progression,
these results suggested that the changes may be
functionally related and might affect a limited number
of signaling pathways.
Functional relationships among differentially expressed
kinases
To identify putative kinase markers of CRC development,
we focused on those kinases that exhibited changes at both
the mRNA and protein levels. Of 230 differentially
expressed PK genes and 42 proteins, 24 exhibited changes
at the transcriptional and protein levels. Of these, 20 were
consistent in the direction of change (Table 2). It should be
noted, however, that despite concordance in the direction of
the change, the magnitude of the change differed consid-
erably at the mRNA and protein levels for some proteins/
genes.
The most significant functional annotations of the 20
PKs that exhibited concordant changes at the transcriptional
and protein levels are listed in Table S8. These PKs were
associated with a wide spectrum of developmental process-
es, as well as survival, tissue and cell morphology, and cell
movement. Strikingly, several functional associations were
related to vascular and nervous system development and
function.
As defined by IPA, the 20 kinases clustered with other
molecules stored in the Ingenuity Knowledge Base into two
interaction networks that were algorithmically generated
based on connectivity. The first network included 14
kinases (score 37, p value<10
−37) and was functionally
associated with cardiovascular system development and
function, embryonic development, and tissue development.
The second network contained the remaining six kinases
(score 13) and was associated with cell cycle, cell death,
and infection mechanisms. Merging the two networks into
one that included all 20 PKs resulted in a network with the
tumor suppressor TP53 as the hub (Fig. 2 and Table S9).
Potential markers of CRC progression
The expression of the selected 20 PKs was finally evaluated
by qRT-PCR in 83 tissue samples (Fig. 3 and Table S10).
Overall, the results of the qRT-PCR were in agreement with
the results of the large-scale analysis of the transcriptomic
ab
Fig. 1 PCA. The first two
principal components were
determined based on the
expression of 792 PK probe sets
from the mRNA microarray
survey (a) and 90 PKs from the
proteomic analysis (b). AC
adenocarcinoma, AD adenoma,
NC normal colon
J Mol Med (2012) 90:447–456 449and proteomic datasets, with the exception of SFRS protein
kinase 2 (SRPK2), fyn-related kinase (FRK), and cAMP-
dependent protein kinase catalytic beta (PRKACB).
For these three kinases, the direction of the change in
gene expression by qRT-PCR was different from that
shown by transcriptomic/proteomic profiling in at least
one pair-wise comparison. Moreover, the expression of
MST4 kinase correlated with AC staging (Spearman=
0.537; p=0.007) and significantly differentiated B1 vs. B2
(p=0.0475) and B1 vs. C2 (p=0.0061) stages of AC
(Fig. S2).
When subjected to hierarchical clustering, the qRT-PCR
expression patterns clearly distinguished NC samples (with
the exception of one sample) from all other neoplastic
tissues (Fig. 4). The NC samples consisted of specimens
derived from normal epithelium adjacent (>5 cm) to
adenocarcinoma (NC-A), as well as tissue from healthy
individuals obtained during colonoscopy (NC-D). Interest-
ingly, the expression profiles distinguished five of six NC-
D tissue samples from NC-A. One possibility for this
distinction is that the cancer tissue might influence gene
expression within the adjacent normal epithelium. It is also
noteworthy that the expression of TAO kinase 3 (TAOK3)
was significantly different (p<0.001) between these two
types of NC (Fig. 3). This observation may have diagnostic
implications, since TAOK3 expression appears to be sup-
pressed within colonic epithelium in the vicinity of
carcinoma.
To determine if differences measured on the mRNA
and protein levels correspond with kinases activity,
kinome profiling was performed using PepChip Kinom-
ics peptide array (Electronic supplementary materials).
Eight of the selected 20 PKs were represented by their
substrates on the array, and for seven of them, the
Table 1 Trends in PK expression during progression from normal colonic mucosa to adenoma and from adenoma to colorectal adenocarcinoma
Difference in fold-change in 
two pair-wise comparisons
a
Graphical depiction of trends
b
of changes 
Number (percent) of differentiating  
PK genes or proteins 
Transcriptome (genes) 
n = 230 
Proteome (proteins) 
 n = 42 
1 26  (11.3)  7  (16.7) 
2 27  (11.7)  0  (0) 
3 123  (53.5)  13  (31.0) 
4 40  (17.4)  12  (28.6) 
5 14  (6.1)  10  (23.8) 
AC AC AD AD NC NC
AC AC
AC AC AD AD
AD AD
NC NC
NC NC
NC NC
AC AC AD AD
AC AC
NC NC AD AD
AC AC
AD AD
AC AC NC NC
AD AD
NC normal colon, AD adenoma, AC adenocarcinoma
aPair-wise comparisons were between AD and NC and between AC and AD. Differences in fold-change between groups of ≥1.5 are represented
by the solid arrows; changes <1.5 are represented by the dashed arrows
bTrend 1 represents PKs that exhibited significant change only in AC vs. NC comparison. Trend 2 exhibits PKs progressively up- or down-
regulated from NC to AD and AD to AC. Trend 3 represents changes in expression upon progression from NC to AD with no corresponding
changes in the transition from AD to AC. Changes associated with progression to malignancy (AC vs. AD) with no corresponding changes in the
early stages of the neoplastic process were classified as trend 4. Trend 5 represents regressive changes (opposite direction in each comparison)
450 J Mol Med (2012) 90:447–456differentiating results of kinase activity were obtained for
at least one tissue pair-wise comparison (Table S11). The
activity of four PKs was in agreement, while two PKs
exhibited an opposite activity when compared to tran-
scriptomic and proteomic directions of their expression.
For the protein kinase C (PKC) delta (PRKCD), six
substrates, out of 18 on array, showed differential
phosphorylation, two in agreement with expression results
and four in opposite direction.
The activity of the one of the selected PKs, STK24, was
also analyzed by its immunoprecipitation from pooled
tissue samples, followed by phosphorylation in vitro assay
(see Electronic supplementary materials for details). As
presented in Fig. S3a, the STK24 activity was increased in
AD and AC tissues, compared with NC. That result was in
agreement with immunoblot analyses performed on the
same tissue samples, which revealed an increased amount
of STK24 kinase in AD and AC (Fig. S3b). However, these
results are in contrast to our findings from the large-scale
transcriptomic/proteomic surveys.
Discussion
Avariety of proliferative disorders, including cancers, result
from deregulated signaling through various PK-mediated
pathways, leading to disturbances in cellular homeostasis
and uncontrolled cell growth [2]. As inducible PKs are the
key elements in phosphorylation-based signal transduction
networks, the analysis of particular tumor kinomes may
provide valuable information on tumor-specific aberrant
signaling. Therefore, the evaluation of tumor kinome
profiles may be useful for the selection of PK candidates
for targeted anti-cancer therapy.
Genomic analyses of kinome profiles indicate that nearly
all human tumors carry at least one mutation in a gene
coding for a kinase or phosphatase [4], and several kinase
inhibitors selected against altered genes have been shown to
possess anti-tumor efficacy in patients with particular
genetic alterations. However, the effects of these mutations
on gene expression or encoded protein activity may not
always be straightforward or predictable.
Table 2 PKs exhibiting concordant changes in expression at the transcriptional and protein levels during CRC progression
Symbol Swiss ID Name Transcriptomics Proteomics
AD/
NC
AC/
AD
AC/
NC
AD/
NC
AC/
AD
AC/
NC
CABC1 Q8NI60 Chaperone activity of bc1 complex-like 2.84 0.63 1.78 3.13* 0.40* 1.25
EPHB2 P29323 EPH receptor B2 5.80 0.62 3.61 1.81* 0.62* 1.13
EPHB3 P54753 EPH receptor B3 23.72 0.44 10.37 2.92* 0.67* 1.95*
EPHB4 P54760 EPH receptor B4 3.32 0.73 2.42 2.35* 0.58* 1.38
SRPK1 Q96SB4 SFRS protein kinase 1 2.23 0.93 2.07 1.91 1.04 1.98
SRPK2 P78362 SFRS protein kinase 2 2.15 1.05 2.25 1.06 1.65 1.75
VRK1 Q99986 Vaccinia related kinase 1 2.84 1.28 3.65 1.03 1.67 1.72
VRK2 Q86Y07 Vaccinia related kinase 2 2.27 1.00 2.27 1.54* 0.77* 1.19*
VRK3 Q8IV63 Vaccinia related kinase 3 0.67 0.98 0.65 0.77* 0.82 0.63
CAMK2D Q13557 Calcium/calmodulin-dependent protein kinase (CaM kinase) II
delta
0.55 0.64 0.35 0.68* 0.96 0.66*
GUCY2C P25092 Guanylate cyclase 2C (heat stable enterotoxin receptor) 0.88 0.43 0.38 0.82* 0.59* 0.48*
PRKCD Q05655 Protein kinase C, delta 0.44 0.90 0.39 0.45* 1.05 0.47*
RPS6KA1 Q15418 Ribosomal protein S6 kinase, 90 kDa, polypeptide 1 0.46 0.84 0.39 0.57* 1.01 0.57*
TAOK3 Q9H2K8 TAO kinase 3 0.70 0.80 0.56 0.48* 1.39* 0.67*
STK24 Q9Y6E0 Serine/threonine kinase 24 (STE20 homolog, yeast) 0.64 1.04 0.66 0.64* 1.10* 0.71*
PDGFRB P09619 Platelet-derived growth factor receptor, beta polypeptide 1.34 2.07 2.78 1.03 3.15* 3.23
BAZ1B Q9UIG0 Bromodomain adjacent to zinc finger domain, 1B 1.17 1.47 1.72 1.22* 1.41* 1.72*
PRKACB P22694 Protein kinase, cAMP-dependent, catalytic, beta 0.75 0.27 0.20 1.51 0.38* 0.57
FRK P42685 Fyn-related kinase 0.21 1.15 0.24 0.49 1.89* 0.93
MST4 Q9P289 Serine/threonine-protein kinase MST4 1.30 1.82 2.36 0.64* 1.55* 1.00
Data in italics indicate down-regulated PKs, while data in bold indicate up-regulated PKs with an FC≥1.5
NC normal colon, AD adenoma, AC adenocarcinoma
*q≤0.05, significant differences in quantitative proteomic study [6]
J Mol Med (2012) 90:447–456 451Our analysis of datasets obtained by integrated tran-
scriptomic and proteomic profiling of CRC tissue samples
[6] identified 20 PKs which exhibited concordant changes
at the transcriptional and protein levels during CRC
progression (Table 2). The expression status of these 20
selected PKs was independently validated by qRT-PCR, in
which the direction of the change in expression of 17 genes
was consistent with the microarray results. The discrep-
ancies between the expression results for the remaining
three genes may stem from methodological differences
inherent in both methods. For example, for the array
results for SRPK2, multiple probe sets (203181_x_at;
214931_s_at; 1558254_s_at; 230091_at; 203182_s_at) tar-
geting several gene isoforms were taken into consideration
to measure the total mRNA expression. However, the qRT-
PCR primers used here span a cDNA product that omits the
Fig. 2 Merged interaction network of 20 PKs whose expression is
differentially regulated during CRC progression. The network was
generated by IPA. Gene products are represented as nodes and
biological relationships between two nodes as edges. All edges are
supported by at least one reference from the literature or from
canonical information stored in the Ingenuity Pathways Knowledge
Base. Node shapes symbolize functional class of the gene product, as
specified in the legend. A description of the molecules included in the
interaction network is presented in Table S9. The names of the 20
kinases are located over the filled triangles
452 J Mol Med (2012) 90:447–456isoform targeted by the 214931_s_at probe set. Discrep-
ancies in the reproduction of microarray results by qRT-
PCR were observed previously in ours and others’ studies
[7, 8].
Fig. 4 Hierarchical clustering of PK mRNA expression data. The
results from qRT-PCR analysis of 20 PKs (Table S10) were used to
generate the cluster tree. Red indicates expression levels greater than
the mean, and green indicates expression levels lower than the mean.
AC adenocarcinoma, AD adenoma, NC-A normal colon epithelium
adjacent (>5 cm) to AC, NC-D normal colon epithelium from healthy
individuals
Fig. 3 Analysis of mRNA expression levels of 20 PKs in individual
tissue samples. AC adenocarcinoma (n=24); AD adenoma (n=39); NC
normal colon (n=20). One microgram of total RNA was reverse-
transcribed to generate cDNA and then q-PCR was performed using
SYBR Green I chemistry. Data are presented graphically in scatter
plots. Green horizontal bars indicate means and red whiskers indicate
standard deviation. Differences were analyzed using the Mann–
Whitney test. Open and filled circles in the TAOK3 chart refer to
NC tissue adjacent (>5 cm) to AC (NC-A) and NC obtained from
healthy individuals (NC-D), respectively
J Mol Med (2012) 90:447–456 453Most CRCs progress through adenoma to carcinoma as a
consequence of altered genetic information. Cancer com-
plexity at the gene level is likely traced to a limited number
of altered genetic pathways. Recently, we applied
microarray-based gene expression profiles to describe gene
regulatory networks, and identified several signaling and
metabolic pathways altered in colon tumors [5]. Networks
involved in cell proliferation and differentiation, the
regulation of gene expression, DNA repair, and cell growth
and survival were found to be significantly altered between
NC and colon tumors, while those representing the
signaling pathways (TGF-beta, Wnt, PPAR, calcium) or
amino acid and lipid metabolism were altered between AD
and AC.
Analysis with the IPA application showed that all 20
selected PKs may be included in one network with the
tumor suppressor TP53 as the hub (Fig. 2), suggesting that
the kinases differentially expressed during CRC progres-
sion are those most commonly associated with the p53
signaling pathway. Interestingly, p53 is considered the
predominant alteration in colon cancer, appearing on
different levels of molecular interaction networks modeling
oncogenic signaling in the colon [5].
Strikingly, three families of PKs were overrepresented
among the 20 selected kinases: Eph receptors (three
members), vaccinia-related kinases (VRKs; three members,
which comprises the entire family), and SRPKs (two
members). Hierarchical clustering of mRNAs of 83 tissue
samples segregated the selected 20 PK genes into three
groups (Fig. 4). The first group represented PKs whose
expression was increased during progression to AD from
NC epithelium and suppressed during malignant transfor-
mation of AD to AC. This group included three represen-
tatives of the Eph family (EPHB2, EPHB3, and EPHB4), as
well as SRPK1, BAZ1B, VRK2, CABC1, and GUCY2C. The
second cluster contained genes that were down-regulated
during CRC progression and included VRK3, CAMK2D,
PRKCD, RPS6KA1, TAOK3, STK24, FRK, and SRPK2.
The third cluster was more complex and included two up-
regulated PK genes (VRK1 and MST4); PRKACB, which
was down-regulated; and PDGFRB, which was overex-
pressed during malignant transformation of AD into AC.
Half of the selected PKs were previously described as
changed in colorectal tumors or colon cancer cells,
including the Eph receptors, SRPK1/2, GUCY2C, PRKCD,
RPS6KA1, PRKACB, PDGFRB, and FRK. The PKs most
widely reported to be altered in colon cancer are the Eph
receptors, which play key roles in the maintenance of cell
architecture and in the regulation of cell adhesion and
migration (reviewed in [9]). During colorectal tumorigen-
esis, high expression of crypt EPHB2 and EPHB3 in ADs
suppresses tumor progression by a mechanism described as
tumor cell compartmentalization, while somatic mutations
and promoter hypermethylation in the EPHB2 and EPHB4
genes were identified as potential mechanisms of receptor
silencing [10].
Overexpression of SRPK1 has been demonstrated in
breast and colonic tumors [11]. Reduced expression of
PRKCD was reported in primary human and rat colonic
neoplasms, and in several colon AC cell lines [12]. FRK is
expressed in epithelial-derived human tissues and cancer
cell lines, including breast and colon cancer cells [13].
Guanylyl cyclase C (GUCY2C) maintains homeostasis and
genomic integrity in intestinal cells and acts as a tumor
suppressor [14]. Amplification of RPS6KA1 was reported in
breast and prostate cancers [15], and genetic variation in
RPS6KA1 may be associated with CRC risk [16]. PRKACB
was implicated in the progression of colon and prostate
cancers [17] and platelet-derived growth factor beta-
receptor (PDGFRB) in lung and colon cancers [18].
The results of the current study show that VRK1/2,
MST4, and CAMK2D are aberrantly expressed in colonic
tumors. Moreover, this study is the first to report the
aberrant expression of TAOK3, STK24, BAZ1B, CABC1,
and VRK3 kinases in tumor tissue. VRKs comprise a new
STK subfamily with three members [19]. VRK1 protein
accumulates in lung carcinomas carrying TP53 mutations
[20] and in head and neck squamous cell carcinomas [19],
whereas differential expression of VRK2 was demonstrated
in estrogen receptor-negative breast cancer [21]. TAOK3,
STK24, and MST4 are STE20-related STKs that belong to
the germinal center kinase subfamily and are regulated by
epidermal growth factor receptor (EGFR) activation [22].
MST4 expression is increased during prostate cancer
progression, and TAOK3 expression is elevated in prostate
cancer cells [22, 23]. Decreased expression of STK24 was
shown to enhance the migration potential of breast cancer
cells [24]. Ca
2+/calmodulin-dependent PK II (CaMKII)
phosphorylates several important proteins in response to
increasing intracellular Ca
2+ concentration and is involved
in the non-canonical Wnt/Ca
2+ signaling pathway. In-
creased activity of CaMKII has been detected in endome-
trial [25] and prostate cancer cells in culture [26]; however,
little is known about the role of the CaMKIIδ isoform
(encoded by CAMK2D) in cancer.
The above-listed PKs are implicated in many aspects of
cancer growth. By contrast, to date there are no reports of
altered BAZ1B, CABC1, or VRK3 expression in tumors.
BAZ1B encodes an atypical TK member of the bromodo-
main protein family, which plays a central role in
chromatin-dependent regulation of transcription [27].
CABC1 (chaperone activity of bc1 complex like) encodes
a mitochondrial protein, the expression of which is induced
by p53 in response to DNA damage [28]. CABC1 and
VRK3 likely lack phosphorylation activity despite the
presence of a PK domain (UniProt database).
454 J Mol Med (2012) 90:447–456Since changes in mRNA or protein levels do not
necessarily result in changes in protein activity, the results
should be confirmed by kinome profiling and analysis of
kinase activity before conclusions can be drawn regarding
kinase function in CRC progression. In fact, we have found
rather week concordance between PK activities and the
results of large-scale surveys which might be explained by
the differences inherent to each of these methods. In
addition, although several groups have used peptide arrays
for kinome activity analysis [29, 30], this methodology is
still in an early stage of development, and important
biological and technical challenges remain to be resolved. In
a consequence, the differences in phosphorylation levels of
potential substrates of a kinase on array (also of opposite
direction)hasbeenaquitecommonphenomenonobservedfor
kinases represented on array by several substrates [29–31].
One of the major caveats to kinome arrays is that they
tend to generate false-positive or false-negative results.
There are several reasons for this, including: (1) peptide
substrates on the array may be exposed to kinases to which
they would never be exposed in the cell, (2) consensus
peptides can often potentially be phosphorylated by several
kinases, (3) consensus sequences on the array may not be
the preferred substrate for a given kinase, and (4) peptide
substrates may be recognized by the correct kinase but with
lower or higher efficiency than in the context of an intact
protein. Furthermore, not all potential substrates of a PK are
phosphorylated to the same extent [29–31]. We attempted
peptide array measurements, but for the reasons mentioned
above, the results were insufficient to draw any meaningful
conclusions.
The other approach to study kinase activity is in vitro
phosphorylation reaction with kinase-specific substrate.
However, the data acquired with a monoclonal antibody
to determine the activity (Fig. S3a) and amount of STK24
kinase (Fig. S3b) were not consistent with STK24 mRNA
obtained by qRT-PCR/transcriptome and protein levels by
proteomic datasets (Fig. 3 and Table 2). The inconsistency
between immunoblot and proteomic results could be
explained by the methodological differences inherent to each
of these approaches. For example, quantitative MS analyses
allow recognition of multiple peptides derived from a given
protein, therefore enabling more reliable protein abundance
measurement,whiletheuseofmonoclonalantibodiesnarrows
the analysis to specific protein isoforms.
The discrepancies between expression and activity levels
of kinase were reported by others previously. Gulmann et
al. demonstrated that levels of activated Erk, p38, and JNK
kinases were decreased by 25–50% in CRCs as compared
to normal tissue, although total protein levels were similar
or even elevated in the cancer tissue samples [32].
Similarly, EGFR expression was reported to be increased
in many ACs, including Barrett’s carcinoma and Barrett’s
mucosa [33]; however, its activity is decreased in Barrett’s
samples when compared with normal squamous epithelium
[34]. This discrepancy is likely explained by differential
expression/activity of upstream proteins, resulting in differ-
ential particular kinase activation, or possibly by the
presence of different kinase isoforms, with different
mechanisms of activation and/or substrate specificity. In
the case of STK24, two isoforms were identified that
differentially regulate MAPK pathways as a consequence of
differential regulation of these two kinases by protein
kinase A (PKA) [35].
To summarize, in addition to the kinases previously
described as changed in tumor tissues, we report in the
current study the aberrant expression of several kinases in
CRC for the first time, including CABC1, BAZ1B,
CAMK2D, VRK3, STK24, and TAOK3. These findings
may be of diagnostic importance in terms of CRC emergence
and the development of novel targeted therapeutics.
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